Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Pharmacotherapy for Smoking Cessation
NCT02501265Phase 2Completed
- Sponsor
- Duke University
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupropion in nicotine dependence (4 arms), sponsored by Duke University. Primary endpoint: Biochemically-confirmed 30-day Continuous Smoking Abstinence. Started Jun 2017; status: completed.
02
Drugs
bupropion
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT02501265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501265.